- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00424229
Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]
Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31]
Study Overview
Detailed Description
Subjects meeting all inclusion and exclusion criteria will receive lenalidomide
lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1-21, every 4 weeks.
Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for assessment of disease progression) evaluations
Subjects may participate in the study for up to 52 weeks ( in patients still responding after 52 weeks, the drug wil continue to be supplied).
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: .Pierre FENAUX, Professor
- Phone Number: 0033148955070
- Email: pierre.fenaux@avc.aphp.fr
Study Contact Backup
- Name: Fatrima-Zohra HAMZA, CRA
- Phone Number: 0033148955890
- Email: fatima.hamza@aphp.fr
Study Locations
-
-
-
Angers, France, 49033
- Recruiting
- CHU Angers
-
Contact:
- Mathilde HUNAULT-BERGER, MD
- Phone Number: 0033241354475
- Email: MHunault@chu-angers.fr
-
Principal Investigator:
- HUNAULT-BERGER, MD
-
Lille, France, 59057
- Recruiting
- CHRU Hurriez
-
Contact:
- Bruno QUESNEL, Profesor
- Phone Number: 0033320446640
- Email: b-quesnel@chru.fr
-
Principal Investigator:
- QUESNEL, Professor
-
Marseille, France, 13273
- Recruiting
- Hopital Paoli Calmette
-
Contact:
- Norbert VEY, MD
- Phone Number: 0033431223695
- Email: veyn@marseille.fnclcc.fr
-
Principal Investigator:
- VEY, MD
-
Sub-Investigator:
- CHARBONNIER, MD
-
Sub-Investigator:
- GASTAUT, Professor
-
Sub-Investigator:
- BOUABDALLAH, MD
-
Sub-Investigator:
- REY, MD
-
Sub-Investigator:
- STOPPA, MD
-
Nantes, France, 44093
- Recruiting
- Hôpital Hotel Dieu
-
Contact:
- Jean-Luc HAROUSSEAU
- Phone Number: 0033240083271
-
Principal Investigator:
- Jacques Delaunay
-
Nice, France, 06202
- Recruiting
- Hôpital Archet
-
Contact:
- Laurence LEGROS
- Phone Number: 0033492035844
- Email: legros.l@chu-nice.fr
-
Principal Investigator:
- LEGROS, MD
-
Paris, France, 75679
- Recruiting
- Hopital Cochin
-
Contact:
- Francois DREYFUS, Professor
- Phone Number: 003358412120
- Email: francois.dreyfus@cch.aphp.fr
-
Principal Investigator:
- DREYFUS, Professor
-
Paris, France, 75475
- Recruiting
- Hoiptal St Louis
-
Contact:
- Herve DOMBRET, Profesor
- Phone Number: 0033142499643
- Email: herve.dombret@sls.aphp.fr
-
Principal Investigator:
- Herve Dombret
-
Poitiers, France, 86021
- Recruiting
- Hôpital Jean-Bernard
-
Contact:
- Francois GUILHOT, Professor
- Phone Number: 0033549444201
- Email: f.guilhot@chu-poitiers.fr
-
Principal Investigator:
- GUILHOT, Profesor
-
Sub-Investigator:
- ROY, MD
-
Rouen, France, 76 038
- Recruiting
- Centre Henry Becquerel
-
Contact:
- Aspasia Stamatoullas, MD
- Phone Number: 33 2 32 08 22 88
- Email: aspsta@rouen.fnclcc.fr
-
Principal Investigator:
- Aspasia Stamatoullas
-
Toulouse, France, 31059
- Recruiting
- CHU Purpan
-
Contact:
- Odile BEYNE-RAUZY, Doctor
- Phone Number: 0033561779679
- Email: beynerauzy.o@chu-toulouse.fr
-
Principal Investigator:
- Odile BEYNE-RAUZY
-
Vandoeuvre, France, 54511
- Recruiting
- CHU Brabois
-
Contact:
- Agnes GUERCI-BRESLER, MD
- Phone Number: 0033383153281
- Email: a.guerci@chu-nancy.fr
-
Principal Investigator:
- GUERCI-BRESLER, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years at the time of signing the informed consent form
- MDS with IPSS scores Int-2 or high with deletion 5q(31)
- Prior thalidomide allowed
- Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC < 13,000/mm3 according to FAB classification) that meets IPSS criteria for intermediate-2 or high-risk disease and has an associated del 5q[31] (the deleted chromosomal region must include 5q[31]), with or without additional cytogenetic abnormalities
Exclusion Criteria:
- Pregnant or lactating females
- Prior therapy with lenalidomide
- MDS with IPSS scores low or Int-1
- Clinical neuropathy of greater than grade 2
- Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML)
- Recombinant human erythropoietin (rHuEPO) therapy received within 28 days
- Use of androgens other than for treating hypogonadism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Primary: Complete Response; Partial ResponseSecondary: Hematological Improvement
|
Collaborators and Investigators
Investigators
- Study Director: Pierre FENAUX, Profesor, Groupe Francophone des Myelodysplasies
- Study Director: Sara Burcheri, Groupe Français des Myélodysplasies
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- GFM-REV-2006-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on LENALIDOMIDE
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Samsung Medical CenterRecruitingRelapsed and/or Refractory Non-Hodgkin T-cell LymphomaKorea, Republic of